Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010029174 - METHOD FOR CLASSIFYING A CANCER PATIENT AS RESPONDER OR NON-RESPONDER TO IMMUNOTHERAPY

Publication Number WO/2010/029174
Publication Date 18.03.2010
International Application No. PCT/EP2009/061888
International Filing Date 14.09.2009
IPC
C12Q 1/68 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/6842
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6803General methods of protein analysis not limited to specific proteins or families of proteins
6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
Applicants
  • GLAXOSMITHKLINE BIOLOGICALS S.A. [BE]/[BE] (AllExceptUS)
  • DUPONT, Pierre, Raphael [BE]/[BE] (UsOnly)
  • GAULIS, Swann, Romain, Jean-Thomas [FR]/[BE] (UsOnly)
  • HELLEPUTTE, Thibault, Marc [BE]/[BE] (UsOnly)
Inventors
  • DUPONT, Pierre, Raphael
  • GAULIS, Swann, Romain, Jean-Thomas
  • HELLEPUTTE, Thibault, Marc
Agents
  • LOVATT, Victoria, Jayne
Priority Data
0816867.615.09.2008GB
61/192,04215.09.2008US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR CLASSIFYING A CANCER PATIENT AS RESPONDER OR NON-RESPONDER TO IMMUNOTHERAPY
(FR) MÉTHODE
Abstract
(EN)
Gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and new diagnostic kits and methods are provided. The kits and methods relate to the treatment of specific populations of, for example, cancer patients, as characterised by their gene expression profile, suffering from MAGE expressing tumours. A 33 gene expression signature identifies melanoma patients responding to treatment with MAGE-A3 ASCI.
(FR)
L'invention porte sur des profils d'expression génique, des microréseaux comprenant des séquences d'acides nucléiques représentant des profils d'expression génique, et sur de nouveaux kits de diagnostic ainsi que sur des méthodes. Les kits et procédés portent sur le traitement de populations spécifiques, par exemple, de patients cancéreux, tels que caractérisés par leur profil d'expression génique, souffrant de tumeurs exprimant MAGE.
Also published as
Latest bibliographic data on file with the International Bureau